RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Xynomic Pharma has closed its business combination with Bison Capital Acquisition, becoming a wholly-owned subsidiary of BCAC. BCAC, which will change its name to Xynomic, will issue 42,860,772 new common shares of stock to Xynomic’s shareholders, worth $191.6 million. Another $55 million in shares will be available to Xynomic shareholders if certain objectives are met. Xynomic, founded in 2016, is headquartered in the US with operations in Raleigh, North Carolina and Shanghai. The company is developing three in-licensed novel oncology therapeutics in the US.
Source: China Biotoday
